Keywords: Tumors (Pre-Treatment), High-Field MRI, susceptibility-weighted MRI
Motivation: Knowing the genotype of gliomas is critical for prognostic assessment and treatment selection. 7.0T susceptibility-weighted imaging (SWI) allows visualizing the deep medullary veins and provides additional metabolic information.
Goal(s): We used the asymmetric deep medullary vein (ADMV) sign on 7.0T SWI to predict glioma isocitrate dehydrogenase mutation status and Ki-67 expression level.
Approach: We assessed the ADMV sign and conventional morphological and screening features (P<0.1) via multivariate logistic regression to evaluate the predicted performance.
Results: The ADMV sign on 7.0T images was independently associated with isocitrate dehydrogenase mutation status and Ki-67 index and improved the images’ diagnostic efficacy.
Impact: Discovery of the ADMV sign as an imaging biomarker and the advantages of 7.0T MRI may help markedly improve the diagnosis and management of gliomas and may have broader applications in medical imaging and biomarker development.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords